PRKCDBP Methylation is a Potential and Promising Candidate Biomarker for Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2022.102.03
- Author:
Jing LI
1
;
Lin QI
1
;
Mingfang ZHANG
1
;
Caiyun YAO
1
;
Jinan FENG
1
;
Zhonghua ZHENG
2
;
Chujia CHEN
2
;
Shiwei DUAN
2
;
Yuanlin QI
1
Author Information
1. School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China.
2. Medical Genetics Center, School of Medicine, Ningbo University, Ningbo 315211, China.
- Publication Type:Journal Article
- Keywords:
DNA methylation;
Lung neoplasms;
PRKCDBP
- MeSH:
Biomarkers/metabolism*;
Carcinoma, Non-Small-Cell Lung/pathology*;
Cell Line, Tumor;
DNA Methylation;
Gene Expression Regulation, Neoplastic;
Humans;
Intracellular Signaling Peptides and Proteins/genetics*;
Lung Neoplasms/pathology*;
Promoter Regions, Genetic
- From:
Chinese Journal of Lung Cancer
2022;25(2):78-85
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:The occurrence and development of lung cancer are closely linked to epigenetic modification. Abnormal DNA methylation in the CpG island region of genes has been found in many cancers. Protein kinase C delta binding protein (PRKCDBP) is a potential tumor suppressor and its epigenetic changes are found in many human malignancies. This study investigated the possibility of PRKCDBP methylation as a potential biomarker for non-small cell lung cancer (NSCLC).
METHODS:We measured the methylation levels of PRKCDBP in the three groups of NSCLC tissues. Promoter activity was measured by the dual luciferase assay, with 5'-aza-deoxycytidine to examine the effect of demethylation on the expression level of PRKCDBP.
RESULTS:The methylation levels of PRKCDBP in tumor tissues and 3 cm para-tumor were higher than those of distant (>10 cm) non-tumor tissues. Receiver operating characteristic (ROC) curve analysis between tumor tissues and distant non-tumor tissues showed that the area under the line (AUC) was 0.717. Dual luciferase experiment confirmed that the promoter region was able to promote gene expression. Meanwhile, in vitro methylation of the fragment (PRKCDBP_Me) could significantly reduce the promoter activity of the fragment. Demethylation of 5'-aza-deoxycytidine in lung cancer cell lines A549 and H1299 showed a significant up-regulation of PRKCDBP mRNA levels.
CONCLUSIONS:PRKCDBP methylation is a potential and promising candidate biomarker for non-small cell lung cancer.
